← Back to headlines
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study
Eli Lilly and Company announced positive findings from the phase 3 VIVID-2 open-label extension study, highlighting sustained efficacy and safety outcomes for its investigational therapy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
